Business Context and Reporting Period
Company: Biomerica, Inc. (BMRA)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended August 31, 2024
Business Overview: Biomerica is a global biomedical technology company developing diagnostic and therapeutic products, primarily focusing on gastrointestinal diseases (e.g., inFoods® IBS) and point-of-care testing. The company operates as a single segment with manufacturing in the U.S. and Mexico.
Key Financial Metrics
| Metric | Q1 2024 (Three Months Ended Aug 31) | Q1 2023 (Three Months Ended Aug 31) |
|---|---|---|
| Net Sales | $1,807,000 | $1,713,000 |
| Gross Profit | $289,000 | $412,000 |
| Gross Margin | 16.0% | 24.1% |
| Operating Loss | $(1,368,000) | $(1,232,000) |
| Net Loss | $(1,316,000) | $(1,132,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.08) | $(0.07) |
| Cash and Cash Equivalents (End of Period) | $2,820,000 | $7,988,000 |
| Working Capital | $4,294,000 | $5,527,000 |
| Total Liabilities | $2,524,000 | $2,663,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 5% ($94,000) driven primarily by a 190% increase in contract manufacturing revenue ($339,000 vs. $117,000). This was partially offset by a 38% decline in Over-the-Counter (OTC) sales due to the absence of large upfront orders seen in the prior year and timing delays in clinical lab orders from Asia.
- Margin Compression: Gross margin declined from 24.1% to 16.0%. Management attributes a 12% negative impact to one-time severance costs from a 15% workforce reduction (RIF) executed in July 2024. Excluding RIF costs, margins are consistent with the prior period.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses rose 16% to $1.36 million, driven by the new sales force ($146,000) and severance costs. Research and Development (R&D) expenses decreased 37% to $297,000 due to reduced clinical trial spending and the commercialization of the inFoods® IBS product.
- Cash Flow: Net cash used in operating activities was $1.34 million, an improvement from $1.67 million in the prior year, largely due to a decrease in inventory levels ($429,000).
Outlook, Risks, and Management Commentary
- Going Concern Warning: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for the next twelve months. Management believes current cash ($2.82 million) is insufficient to meet operating requirements and strategic objectives.
- Capital Strategy: The company is pursuing an "At-The-Market" (ATM) offering to raise up to $5.5 million. However, capital raising is constrained by low stock trading volume (avg. 83,068 shares/day) and price ($0.28 - $0.59 range).
- Cost Reduction: Significant cost-cutting measures are underway, including the 15% workforce reduction and reduced R&D spending, to extend the cash runway.
- Product Focus: Continued focus on commercializing inFoods® IBS and hp+detect™ (H. pylori test). Management is expanding partnerships with gastroenterology groups and reference laboratories.
- Concentration Risk: Two key customers accounted for 55% of net sales in Q1 2024. Two key vendors accounted for 34% of raw material purchases.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $2.82 million cash balance against the stated burn rate and the timeline for securing additional financing.
- ATM Offering Viability: Assess the feasibility of raising capital via the ATM program given the current low stock price and trading volume.
- Customer Concentration: Monitor the stability of the two key customers representing 55% of revenue, particularly the distributor in Asia cited for order delays.
- Margin Recovery: Track whether gross margins improve in subsequent quarters as one-time severance costs are removed from the P&L.
- Product Adoption: Evaluate the commercial traction of inFoods® IBS and hp+detect™ to determine if they can generate sufficient revenue to offset operating losses.